TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.0900nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: <0.100nMAssay Description:Inhibition of PDGFRalphaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: <0.100nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.190nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.240nMAssay Description:Inhibition of human recombinant PDGFRalpha in cell free system after 60 minsMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <0.300nMAssay Description:KIT D816V assay at the APPKM for ATP: In each well of a 384-well assay plate, 0.3 nM of untreated enzyme was incubated in a total of 13 μL of bu...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.418nMAssay Description:Inhibition of human PDGFRalpha using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.430nMAssay Description:Inhibition of PDGFRalpha (unknown origin) by HTRF methodMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.450nMAssay Description:Inhibition of PDGFRalpha (unknown origin)More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.530nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.580nMAssay Description:Inhibition of PDGFRA (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition measured after 6...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of PDGFRalpha (unknown origin) incubated for 1 hr by spectrophotometric analysisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.730nMAssay Description:Compounds may also be assayed as inhibitors of PDGFR in a manner substantially similar to the method described in Roberts, et al., Antiangiogen...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.75nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.793nMAssay Description:Inhibition of human PDGFRalpha using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.960nMAssay Description:Inhibition of PDGFRalpha kinase domain (unknown origin) assessed as reduction in probe peptide substrate phosphorylation by capillary electrophoresisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 0.980nMAssay Description:Inhibition of PDGFRalphaMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:KIT, KIT mutant, and PDGFRα mutant kinase profiling was performed with recombinant enzymes including wild-type KIT, KIT V560G, KIT V559D/T670I, ...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: <1nMAssay Description:Inhibition of PDGFRalpha (unknown origin) using EAIYAAPFAKKK substrate by radioisotope-based P81 filter-binding assayMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Homo sapiens (Human))
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Novartis Institutes Of Biomedical Research (Nibr)
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of PDGFRalpha by TR-FRET analysisMore data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha [D842V](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: <1nMAssay Description:In each well of a 384-well plate, 0.7 ng/ul (8 nM) of PDGFRA D842V (ProQinase 0761-0000-1) was incubated in a total of 12.5 ul of buffer (100 mM HEPE...More data for this Ligand-Target Pair